Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

Slides:



Advertisements
Similar presentations
Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
Advertisements

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
PARPi combinations against HR-proficient tumors.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.
Effect of MI-773 and/or cisplatin in a preclinical model of ACC
Effect of MI-773 dosing on long-term efficacy.
CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
Antitumor immunity caused by DS-8201a.
Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys. Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys.
Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.
In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,
coTCRcys-transduced T cells control tumor growth in vivo.
EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,
Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
Quercetin induces arrest in G1 phase of cell cycle in P39 xenografts.
Quercetin induces apoptosis in P39 xenografts.
Matriptase-2 inhibited breast tumor development in vivo.
The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.
Vascular staining in CWR22R xenograft tumors.
MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.
Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.
The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.
Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.
Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.
GA reduces the growth of Caki-1 tumor xenografts.
Antitumor effects of celastrol in vitro and in vivo.
MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.
Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)
Xenograft regrowth studies.
Growth curve (a) and doubling time (b) of glioma cells.
Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.
A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.
A, decreased vessel formation in basic fibroblast growth factor–supplemented Matrigel plugs excised from mice 10 days after treatment with the combination.
Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.
The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.
A, tumor growth studies in H1975 tumor–bearing mice.
CRA inhibits the growth of human tumor xenografts in vivo.
Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.
Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.
A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.
Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.
Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.
Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.
Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.
Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.
The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.
Putative molecular pathways showing how GSK3β regulates the fate of tumor cells (survival, proliferation, or apoptosis) and influences their sensitivity.
RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
Axial 1advanced technology laboratory animal scanner PET images of [11C]DCMC in (A) MCF-7 and (B) PC-3 tumor-bearing mice. Axial 1advanced technology laboratory.
TAE-684 effectively inhibits the growth of H3122 in vivo.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
PDL192 and inhibit the growth of xenograft tumors.
A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.
BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.
Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.
W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.
In vivo effect of KIN-193 on PTEN-deficient tumors.
Curative effect of W+T treatment in vivo.
Presentation transcript:

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive to temozolomide (GBM2, Rh28, MGMT-deficient), or single-agent talazoparib (KT-10), and two additi... Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive to temozolomide (GBM2, Rh28, MGMT-deficient), or single-agent talazoparib (KT-10), and two additional alveolar rhabdomyosarcoma xenografts (Rh30, Rh41). Combination A (temozolomide 30 mg/kg for 5 days; talazoparib 0.1 mg/kg twice daily for 5 days); combination B (temozolomide 12 mg/kg for 5 days; talazoparib 0.25 mg/kg twice daily for 5 days). Graphs show growth of individual tumors in SCID mice. Malcolm A. Smith et al. Clin Cancer Res 2015;21:819-832 ©2015 by American Association for Cancer Research

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.